Document:

Exhibit

Exhibit 10.1
[Jazz Pharmaceuticals Letterhead]
PERSONAL, PRIVATE AND CONFIDENTIAL
14 May 2012
Patricia Carr
[Address]
Terms and Conditions of Employment
Dear Pat,
On behalf of Jazz Pharmaceuticals PLC (the “Company”), I am very pleased to offer you employment with the Company.
Your employment will be subject to the following terms and conditions.
		
	1.
	POSITION

Your position with the Company will be as Vice President, International Finance.
		
	2.
	COMMENCEMENT DATE

Your employment will be deemed to have commenced on 9 July 2012 and the terms and conditions set out in this letter will take effect from such date.
		
	3.
	PLACE OF WORK

You will be normally based at the Company’s offices at 45 Fitzwilliam Square, Dublin 2, but will be required to travel within Ireland and abroad in carrying out your responsibilities.  For up to an initial period of 6 months, your primary location shall be the offices of Jazz Pharmaceuticals in Palo Alto, CA, USA.  Thereafter, you will be required to travel to the United States of America and other locations from time to time.
		
	4.
	HOURS OF WORK

You will determine your own hours of work and will be required to work the requisite hours and days in order to best perform your duties and to this end a degree of flexibility will be required on your part.  You shall work a minimum of 37.5 hours per week from 9:00 am to 5:30 pm Monday to Friday, with a break of one hour for lunch each day.  Your salary reflects the flexibility required of you.  No extra remuneration will be paid for additional hours worked or where work is required to be performed on a weekend.
		
	5.
	REPORTING STRUCTURE

You will report directly to the SVP, Finance, David Brabazon.  However the reporting structure may change from time to time, at the discretion of the Chief Financial Officer, the Chief Executive Officer or the Board of Directors (the “Board”).

		
	6.
	SALARY

		
	6.1.
	Your initial salary will be €200,000 per annum.  This will be paid to you monthly in arrears on the last day of each month by credit transfer directly to your bank account.  Your salary will be subject to annual review each year on the anniversary of the date of this letter.

		
	6.2.
	All payments to you will be subject to deductions of tax, PRSI, Universal Social Charge and any other deductions required by law or provided for in this letter.  You will be notified each month by the Company of the amount of your gross and net remuneration and of the nature and amount of all deductions.

		
	6.3.
	For the purposes of the National Minimum Wage Act, 2000, the pay reference period shall be a month.  In accordance with section 23 of the Act, you may request from the Company a written statement of your average hourly rate of pay for any pay reference period (other than a current pay reference period) falling within the twelve month period immediately preceding the request.

		
	7.
	SIGNING BONUS

		
	7.1.
	You will be entitled to a one time signing bonus of €16,000 to be paid in coordination with the first possible regular payroll processing, subject to the usual deductions of tax, PRSI, Universal Social Charge and any other deductions required by law or provided for in this letter.

		
	8.
	BONUS

You will be entitled to be considered for a bonus based on your performance.  Any bonus payment will be at the sole discretion of the Board.  You will not be entitled to a bonus if your employment has been terminated, or notice of such termination has been given by either you or the Company, prior to the date the bonus is paid.
		
	9.
	EQUITY

Subject to approval by the Board of Director, your offer includes a grant of options to purchase 20,000 Jazz Pharmaceuticals ordinary shares and a grant of 10,000 restricted stock units (RSUs) giving you a right to receive Jazz Pharmaceuticals ordinary shares at a future date.  Subject to the plan as in effect and your continued employment on each vesting date as per the Company equity plan.
		
	10.
	EXPENSES

All properly vouched and authorised expenses incurred by you on Company business will be reimbursed by the Company.
		
	11.
	HOLIDAYS

You will be entitled to 21 working days holidays (exclusive of all Irish bank and other public holidays in accordance with the Organisation of Working Time Act 1997) in each year.  Your holidays are to be taken by arrangement with the Company, at such time or times that the Company considers to be most convenient having regard to the requirements of your position.
The Company’s holiday year runs from 1 January to 31 December.  Holidays from the previous year may not be carried over to the following year except with the Company’s consent.  Upon notice of termination of employment being served by either party, the Company may, subject to the provisions of the Organisation of Working Time Act 1997, require you to take any unused holidays accrued at that time during any notice period.  Alternatively, the Company may, at its discretion, on termination of the employment, make a payment in lieu of accrued contractual holiday entitlement.

		
	12.
	BENEFIT SCHEMES

Pension Scheme:
The Company has no pension scheme.  The Company does provide access to a personal retirement savings account (PRSA).  If you wish to begin making contributions to a PRSA, please contact Bridget O’Brien.
		
	13.
	DUTIES

You will carry out duties as assigned to you from time to time by the Company.  Your area of work and/or specific responsibilities may be altered from time to time by the Company as the circumstances of the business dictate.
		
	14.
	PERIOD OF EMPLOYMENT

Subject to the provisions of Clauses 16, 17, 16 and 21, your employment will continue until terminated by you or the Company giving the other at least 2 months’ written notice of termination (or, if longer, the period required by law).
		
	15.
	PAYMENT IN LIEU OF NOTICE/ GARDEN LEAVE

Where notice of termination of your employment is given, whether by you or the Company, the Company will have the right to:
		
	15.1.
	pay you in lieu of notice the amount of your entitlement to salary in respect of such notice period; or 

		
	15.2.
	require you to cease performing or exercising during some or all of the remainder of any notice period some or all of the powers, authorities and discretions delegated to you in your employment and/or to cease attending your place of work during such period.

		
	16.
	TERMINATION

Your employment may be terminated without prior notice if, at any time after the date of this letter, you:
		
	16.1.
	are guilty of any material breach or non-observance of the provisions contained in this letter;

		
	16.2.
	are guilty of any serious misconduct in the discharge of the duties of your employment or in connection with or affecting the business of the Company;

		
	16.3.
	commit any serious act of dishonesty or repeated acts of dishonesty;

		
	16.4.
	become of unsound mind; or

		
	16.5.
	are convicted of any offence (other than minor traffic offences or any other offence which in the opinion of the Board does not affect your position with the Company).

		
	17.
	NORMAL RETIREMENT AGE

The Company’s normal retirement age is 65.  Your employment will end automatically on your 65th birthday if it has not terminated before then in accordance with the provisions of this contract.
		
	18.
	ILLNESS

Absences from work for whatever reason must be notified to your Manager as soon as possible on the first day of absence.  Payment of salary for any absences attributable to illness will be at the sole discretion of the Company.

If you are at any time prevented by illness, injury, accident or any other circumstances from discharging all your duties for a period of three consecutive days, then a satisfactory certificate will be required from your doctor in respect of such absence.
The Company reserves the right, at any time, to require you to undergo a medical examination by a Doctor or Consultant nominated by the Company, in which event the Company will bear the cost of such examination.
		
	19.
	DISCIPLINARY RULES AND PROCEDURE

		
	19.1.
	You will conduct yourself with propriety at all times and with due regard for the Company and each of its associated companies and the clients and employees of each such company.

		
	19.2.
	In the event that your conduct or performance falls short of the standards required by the Company or the Board in any respect, (other than cases of misconduct) you will receive at first instance, a verbal warning, followed, if necessary in the event of a repetition, by a written warning which, in appropriate circumstances, may be deemed to be a final written warning.  In the event of further breach of conduct or poor performance, and following due investigation during which you will be afforded an opportunity to make whatever representations you consider appropriate, your employment may be terminated by the Company, with or without notice as is deemed appropriate.  Where appropriate, because of the gravity of your conduct or performance, the Company reserves the right to commence this procedure at any stage.

		
	19.3.
	In order to investigate a complaint against you, the Company may suspend you on full pay for as long as may be necessary to carry out an investigation and hold a disciplinary hearing.

		
	20.
	CONFIDENTIALITY

		
	20.1.
	You will not, except as authorised or required by your duties, reveal to any person, persons or company any information of a confidential or proprietary nature, including any trade secrets, secret or confidential operations, processes or dealings or any information concerning the organisation, business, finances, transactions or affairs of the Company, its subsidiary or associated companies or their existing or potential customers which may come to your knowledge during the period of your employment with the Company (“Confidential Information”).  You will keep all Confidential Information entrusted to you completely secret and will not use or attempt to use any Confidential Information in any manner which may injure or cause loss either directly or indirectly to the Company or any of its subsidiary or associated companies or their existing or potential customers or its or their business or businesses, or may be likely so to do.  This restriction will continue to apply after the termination of your employment without limit in point of time but will cease to apply to information or knowledge which may reasonably be said to have come into the public domain other than by reason of breach of the provisions of this letter.

		
	20.2.
	You will not during the term of your employment with the Company make otherwise than for the benefit of the Company any notes or memoranda relating to any matter within the scope of the business of the Company, its subsidiary or associated companies or their existing or potential customers or concerning any of the dealings or affairs of any such company nor will you either during the term of your employment with the Company or afterwards use or permit to be used any such notes or memoranda otherwise than for the benefit of the Company, it being the intention of the parties that all such notes or memoranda made by you will be the property of the Company and left at its offices upon the termination of your employment with the Company.

		
	21.
	PROPRIETARY RIGHTS

		
	21.1.
	In this Clause 21, “IP” means all intellectual property rights of whatever nature, including copyright (present and future), moral rights, patents, trade marks, design rights and database rights (whether or not any of these is registered and including any applications for registration of any such rights), know-how, Confidential Information and trade secrets and all rights or forms of protection of a similar nature or having similar effect to any of these which may exist anywhere in the world.

		
	21.2.
	You will immediately disclose to the Company any discovery or invention or process or improvement in procedure made or discovered by you (whether or not in conjunction with any other person or persons) while in the employment of the Company in connection with or in any way affecting or relating to the business of the Company, its subsidiary or associated companies or capable of being used or adapted for use therein or in connection therewith (“Inventions”) will forthwith be disclosed to the Company.  All Inventions will belong solely to the Company or such other person, persons or company as the Company may nominate for the purpose.  Any IP developed in whole or in part by you in connection with your employment with the Company will immediately vest in the Company (or a nominee of the Company where the Company requires) absolutely.

		
	21.3.
	If and whenever required so to do (whether during or after the termination of your employment) you will without charge and at the expense of the Company or its nominee apply or join in applying for letters patent or other form of protection for any IP referred to in this Clause 21 and execute all instruments and do all things considered necessary in the absolute discretion of the Company in relation to the said IP including vesting all right and title to such IP when obtained in the Company (or its nominee) as sole beneficial owner, or in such other person as the Company may require.

		
	21.4.
	You irrevocably appoint the Company to be your attorney in your name and on your behalf to execute and do any such instruments or things and generally to use your name for the purpose of giving to the Company (or its nominee) the full benefit of the provisions of this Clause 21.  A certificate in writing signed by any executive or the Secretary of the Company that any instrument or act falls within the authority conferred in this Clause 21.4 will be conclusive evidence that such is the case in favour of a third party.

		
	21.5.
	To the extent that you cannot assign any IP to the Company (or its nominee), it is agreed that any such right (including, where applicable, any moral right, such as a right of paternity or integrity) will be waived as against the Company.  You may not under any circumstances exercise any IP against the Company or any of its subsidiary or associated companies or any nominee of any of them.

		
	22.
	RESTRICTIVE COVENANTS

		
	22.1.
	You may not during the period of your employment with the Company, without prior written consent of the Company, engage, whether directly or indirectly, in any business or employment which is similar to or competitive with the business of the Company or its subsidiary or associated companies or which may in the Company’s opinion impair your ability to act at all times in the best interest of the Company.

		
	22.2.
	You undertake that for a period of 12 months after the date of the termination of your employment, in the Republic of Ireland, you will not, directly or indirectly, be employed, engaged, concerned or interested, in any business directly competing with the products sold by the Company or its subsidiary or associated companies at that time, whether on your own account or in partnership or as an employee, director or manager for any other person.

		
	22.3.
	You also undertake that for a period of 12 months after the termination of your employment, you will not, in competition with the Company or its subsidiary or associated companies, solicit or entice or endeavour to solicit or entice away from the Company any person who was at any time in the twelve months prior to the termination of your employment with the Company employed or engaged by the Company or its subsidiary or associated companies and who, by means of such employment, is or is likely to be in possession of confidential information relating to the Company or its subsidiary or associated companies.

		
	22.4.
	You acknowledge and agree that all of the restrictions contained in this letter are reasonable and necessary to protect the interests of the Company and its subsidiary and associated companies and you agree that the Company may seek equitable remedies to enforce them in addition to any other legal remedies it has.

		
	22.5.
	If any provision in this Clause 22 is deemed to be, or becomes invalid, illegal, void or unenforceable under applicable laws, such provision will be deemed amended to conform to applicable laws so as to be valid and enforceable (including, by way of example, by restricting the area, duration and/or scope of the covenants in to such area, duration and/or scope as would be held reasonable), or if it cannot be so amended without materially altering the intention of the parties, it will be deleted, but the validity, legality and enforceability of the remaining provisions of this letter shall not be impaired or affected in any way.

		
	23.
	DATA PROTECTION ACTS 1988 AND 2003

		
	23.1.
	You hereby acknowledge that during the course of your employment with the Company, the Company will keep personal data and sensitive personal data (e.g. doctor’s certificates or medical reports) relating to you on computer and in manual files/paper files.  You hereby acknowledge and agree that the Company is permitted to hold and process personal information about you as part of its personnel and other business records and may use such information in the course of the Company’s business.  You further agree that the Company may disclose such information to third parties in the event that such disclosure is in the Company’s view required by the proper conduct of the Company’s business.  This clause applies to information held, used or disclosed in any medium.

		
	23.2.
	You acknowledge and give your consent and authorisation to the Company’s monitoring of its communication and electronic equipment where it has a reasonable suspicion of inappropriate use including, without limitation, the Company’s telephone, facsimile, and internet and e-mail systems, and information stored on the Company’s telephone equipment (including floppy disks that are the property of the Company).

		
	24.
	HEALTH & SAFETY

		
	24.1.
	The Company takes seriously its obligations regarding the safety, health and welfare of its employees and in that regard your attention is drawn to the Company safety statement (which is available for viewing on the intranet).  By signing this letter, you agree to take reasonable care of your own safety and health and that of any other persons who may be affected by your acts or admissions while at work.  You also agree to cooperate with the Company and any other person to enable compliance with any provision of the Safety, Health and Welfare at Work Acts 1989 and 2005 and any Regulation made thereunder.

		
	25.
	MISCELLANEOUS PROVISIONS

		
	25.1.
	Notices.  Any notice under this letter will be given in writing and will be deemed to have been duly given if delivered personally to the addressee or the duly authorised agent of the addressee or sent by prepaid registered post to the last known address of the party to whom such notice is given.  Any such notice will be deemed to have been duly given at the time of delivery if delivered personally, or two working days after posting if sent by prepaid registered post.

		
	25.2.
	Entire Agreement.  This letter is in substitution for all previous agreements and undertakings (if any) either written or verbal between the Company and you, and all such agreements and undertakings will be deemed to have been terminated by mutual consent as from the date of your execution of this letter.

		
	25.3.
	Governing Law and Jurisdiction.  This Agreement shall be governed by and construed in accordance with the laws of Ireland, and shall be subject to the exclusive jurisdiction of the Irish courts.

		
	25.4.
	The information contained in this letter constitutes a written statement of particulars of your employment with the Company in accordance with the requirements of section 3 of the Terms of Employment Act 1994.

***
If you choose to accept the terms and conditions of employment set out in this letter, please sign the enclosed copy of the letter and return it to me.
Yours sincerely
   /s/ David Brabazon    14/5/2012    
David Brabazon
Duly authorised for and on behalf of 
Jazz Pharmaceuticals PLC
I accept employment with the Company on the terms and conditions as set out in the Company’s letter of which this is a copy.
Signed:       /s/ Patricia Carr    
Dated:       16/05/2012Exhibit

Exhibit 10.2
[Jazz Pharmaceuticals Letterhead]
PERSONAL, PRIVATE AND CONFIDENTIAL
2 May 2016
Patricia Carr
[Address]

Re: Amended and Restated Change in Control Severance Terms
Dear Patricia:
As was discussed with you, this letter agreement (the “Amendment”) provides the amended and restated terms covering your eligibility for cash severance benefits under certain circumstances related to a Change in Control.  This Amendment is effective as of 15 May 2016, provided that it is signed by both you and Jazz Pharmaceuticals Ireland Limited by this date.  This Amendment amends your contract of employment dated 14 May 2012 (the “Employment Contract”), and it supersedes and replaces the previous letter agreement dated 17 September 2012 which covered your eligibility for severance benefits.  For purposes of this Amendment, you are referred to as the “Executive.”  Your amended and restated severance benefits terms are set forth below.
		
	1.
	Covered Termination:  The Executive will be eligible for the severance benefits (the “Severance Benefits”) set forth in this Amendment in the event of a Covered Termination which is effective on or within twelve (12) months following a Change in Control, subject to the requirements set forth herein.

		
	2.
	Severance Benefits:  The Severance Benefits will consist of a cash severance payment and payments for continued health care insurance coverage, as follows:

a.Cash Severance Benefits: A lump sum cash severance payment will be paid to the Executive in an amount equal to the sum of the following three components (the “Severance Payment”): (1) Executive’s Final Basic Salary multiplied by 100%; (2) the product of the Final Basic Salary multiplied by the Bonus Percentage multiplied by 100%; and (3) the product of the Final Basic Salary multiplied by the Bonus Percentage multiplied by the Bonus Multiplier.  Notwithstanding the foregoing, to the extent applicable, the Severance Payment shall be reduced by any amounts paid to Executive (i) for performance for the calendar year in which the Covered Termination occurs under any bonus plan maintained 

by the Company or an Affiliate (which shall not include any one-time or extraordinary bonus payments provided outside of a plan for performance); (ii) during any period of garden leave immediately preceding the Covered Termination, (iii) qualifying as pay-in-lieu of notice, or (iv) any other severance benefits whether contractual or statutory (including but not limited to any statutory redundancy pay) or other similar benefits payable to the Executive in connection with the Executive’s termination of employment.  The Severance Payment shall be paid to the Executive in a single lump sum payment on the sixtieth (60th) day following the date of the Covered Termination.
By way of example, if the effective date of the Covered Termination is 30 June, Executive’s Final Basic Salary is €100,000, and her target bonus is 30% of basic salary (and Executive has not received any higher annual bonus (i) in either of the last two calendar years prior to the Covered Termination, or (ii) in either of the last two calendar years prior to the Change in Control), the Severance Payment shall be calculated as follows:
(1)    €100,000 x 100% (1.0) = €100,000
(2)    €100,000 x bonus percentage (.3) x 100% (1.0) = €30,000 
(3)    €100,000 x bonus percentage (.3) x 6/12 = €15,000
Total Severance Payment: €100,000 + €30,000 + €15,000 = €145,000
b.Health Continuation Coverage Benefits: To the extent that Executive elects continued private health insurance coverage following the Covered Termination at a level equivalent to the private health insurance coverage available to Executive during her employment, the Employer shall pay the applicable premiums (inclusive of premiums for the Executive’s participating dependents, if any) for such plan coverage for a period of twelve (12) months following the date of the Covered Termination (or such earlier date if the Executive dies, if Executive and/or her dependents are no longer eligible for coverage, or if Executive obtains new employment which includes eligibility for health plan coverage).  The provision of these benefits is subject to health insurance coverage being obtained on normal terms and subject to medical and other underwriting requirements and other terms and conditions.  The Executive shall be required to notify the Employer immediately if the Executive becomes covered by a health insurance plan of a subsequent employer or if the Executive or her participating dependents otherwise cease to be eligible for coverage during the period provided above.  Upon the conclusion of such period of insurance premium payments made by the Employer, the Executive will be responsible for the entire payment of premiums.
		
	3.
	Certain Definitions:

a.“Affiliate” means any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the United States Securities Act of 1933, as amended.

b.“Basic Salary” means Executive’s annual base pay (excluding incentive pay, premium pay, commissions, overtime, bonuses and other forms of variable compensation).
c.“Board” means the Board of Directors of the Company.
d.“Bonus Multiplier” means the quotient obtained by dividing the number of full months that the Executive is employed by the Company or an Affiliate in the year of a Covered Termination by twelve (12).
e.“Bonus Percentage” means the greater of (i) the highest amount of any annual bonus paid to the Executive by the Company or an Affiliate for (x) either of the last two (2) calendar years prior to the date of the Executive’s Covered Termination or (y) either of the last two (2) calendar years prior to the Change in Control, in each case expressed as a percentage of Executive’s annual basic salary paid in the applicable year; or (ii) the higher of the Executive’s target bonus for (x) the calendar year in which the Executive’s Covered Termination occurs or (y) the calendar year in which the Change in Control occurs, in each case expressed as a percentage of Executive’s annual basic salary paid in the applicable year.  For purposes of the foregoing and this Amendment, if the Executive has a title of Vice President on the date of her Covered Termination, the Executive’s target bonus for the calendar year in which the Covered Termination occurs or for the calendar year in which the Change in Control occurs shall mean, in each case, thirty percent (30%) of the Executive’s Basic Salary for such year, notwithstanding any contrary provision set forth in any bonus or other plan maintained by the Company or an Affiliate.
f.“Cause” means the occurrence of any one or more of the following:
		
	(i)
	the Executive’s unauthorised use or disclosure of the confidential information or trade secrets of the Company or its Affiliates which use or disclosure causes material harm to the Company or an Affiliate;

		
	(ii)
	the Executive’s material breach of any written agreement between the Executive and the Company or an Affiliate, or the Executive’s material violation of any statutory duty owed to the Company or an Affiliate, in either case which remains uncured for ten (10) business days after receiving written notification of the breach or violation from the Board or its designee;

		
	(iii)
	the Executive’s material failure to comply with the written policies or rules of the Company or an Affiliate which remains uncured for ten (10) business days after receiving written notification of the breach from the Board or its designee;

		
	(iv)
	the Executive’s conviction of, or plea of “guilty” or “no contest” to, any crime involving fraud, dishonesty, or moral turpitude under the 

laws of any United States or Irish federal, state, or local authority, or any foreign governmental authority;
		
	(v)
	the Executive’s gross misconduct, including but not limited to an attempted or actual commission of, participation or cooperation in, fraud or act of dishonesty against the Company or an Affiliate;

		
	(vi)
	the Executive’s continuing failure to perform assigned duties after receiving written notification of the failure from the Board or its designee;

		
	(vii)
	the Executive’s failure to reasonably cooperate in good faith with a governmental or internal investigation of the Company, or any of its Affiliates, directors, officers, or employees, if the Board or its designee has requested the Executive’s cooperation; or

		
	(viii)
	any action of Executive warranting summary dismissal or termination without prior notice under Executive’s Employment Contract or such other employment agreement of Executive as in effect on the Covered Termination or under applicable employment laws.

g.“Change in Control” means “Change in Control” as defined in the Jazz Pharmaceuticals plc Amended and Restated Executive Change in Control and Severance Benefit Plan (“Executive CIC Plan”).
h.“Companies Act” means the Companies Act 2014 of Ireland, together with all statutory modifications and re-enactments thereof and all statutes and statutory instruments which are to be read as one with, or construed or read together as one with, the aforementioned enactments and every statutory modification and re-enactment thereof for the time being in force.
i.“Company” means “Company” as defined in the Executive CIC Plan.
j.“Constructive Termination” means a resignation of employment by Executive after an action or event which constitutes Good Reason is undertaken by the Company or an Affiliate, or otherwise occurs, provided such action or event is not agreed to by Executive in writing; provided, however, that in order for Executive’s resignation to constitute a Constructive Termination, Executive must (i) provide written notice to the Company’s General Counsel within thirty (30) days after the first occurrence of the action or event giving rise to Good Reason setting forth the basis for such resignation, (ii) allow the Company at least thirty (30) days from receipt of such written notice to cure such action or event, and (iii) if such action or event is not reasonably cured within such period, resign from all positions Executive then holds with the Company and any Affiliate effective not later than ninety (90) days after the expiration of the cure period.

k.“Covered Termination” means either (i) an Involuntary Termination Without Cause, or (ii) a Constructive Termination, in each case effective upon or within twelve (12) months following a Change in Control.
l.“Disability” means Executive’s inability to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than twelve (12) months, and shall be reasonably determined by the Board or its designee on the basis of such medical evidence as the Board or its designee deems warranted under the circumstances.
m.“Employer” means the entity which employs Executive. 
n.“Executive” means Patricia Carr. 
o.“Final Basic Salary” means the higher of Executive’s Basic Salary in effect (x) on the date of her Covered Termination (without giving effect to any reduction in Basic Salary that would constitute Good Reason for Constructive Termination) or (y) immediately prior to the Change in Control; provided, however, that if the Executive has, during the twelve (12) months prior to the date of her Covered Termination or the Change in Control, as applicable, taken a voluntary pay reduction, then Executive’s Final Basic Salary will be determined without regard to such voluntary pay reduction.
p.“Good Reason” means the occurrence of any one or more of the following actions or events without Executive’s written consent:
		
	i.
	one or more reductions in Executive’s Basic Salary that results in a total reduction in Executive’s Basic Salary, as in effect immediately prior to the Change in Control or any higher Basic Salary in effect following the Change in Control, by more than ten percent (10%);

		
	ii.
	a relocation of Executive’s principal place of employment that increases Executive’s one-way commute by more than thirty-five (35) miles;

		
	iii.
	a substantial reduction in Executive’s authority, duties, or responsibilities (and not simply a change in reporting relationships) as in effect immediately prior to the effective date of the Change in Control; provided that, if (i) Executive continues to hold the same position but the size of Executive’s employing entity (or the business unit to which Executive is assigned) has decreased significantly or (ii) neither the Company nor the Employer continues to be a publicly traded corporation, Executive’s authority, duties and responsibilities will be considered to be substantially reduced; or

		
	iv.
	a reduction in the Executive’s title.

q.“Involuntary Termination Without Cause” means a termination by the Company or an Affiliate of Executive’s employment relationship for any reason other than for Cause.  For purposes of the foregoing and this Amendment, a termination of employment due to Executive’s death or Disability shall constitute an Involuntary Termination Without Cause.
		
	4.
	Additional Terms:  The following additional terms shall apply:

a.Release and Other Requirements for Receipt of Severance Benefits:  In order to be eligible to receive, and prior to receipt of any of the Severance Benefits, the Executive must execute a general waiver and release and return such release to the Company within the time period specified therein, but in no event more than forty-five (45) days following the date of the Covered Termination, and such release must become effective in accordance with its terms but in all cases not later than the sixtieth (60th) day following the Covered Termination.  No release shall require the Executive to forego any unpaid salary, any accrued but unpaid vacation pay, or any vested or earned benefits payable pursuant to the Executive’s Employment Contract (or other employment agreement in effect as of the Covered Termination) or by law.  The Company, in its sole discretion, may modify the form of the required release to comply with applicable law and shall determine the form of the required release.  In addition to such release, Executive also must return all property of the Company or an Affiliate which Executive has in her possession or control.
b.Mitigation: The Executive shall not be required to mitigate damages as a condition of the Severance Benefits by seeking other employment or otherwise.  Similarly, no amount of the Severance Benefits shall be reduced by any compensation earned by the Executive as a result of employment by another employer or any retirement, death, or disability benefits received by such Executive (or her estate) after the date of the Executive’s termination of employment with the Company or an Affiliate, except for Severance Benefits relating to payments for health continuation coverage as provided above.
c.Tax Withholding, Contributions: All payments under this Amendment will be subject to all applicable deductions and withholdings of tax, PRSI, Universal Social 

Charge, and any other deductions which are required pursuant to the terms of the Executive’s employment or by law, or which are provided for in the Executive’s Employment Contract and/or this Amendment.
d.Application of Section 252 and 253 of the Companies Act: This Amendment is entered into for the benefit of Executive in the ordinary course of her employment.  It is not intended to provide for any payment by way of compensation for loss of office or consideration for or in connection with the retirement from office of a director of the Company in connection with the transfer of the whole or any part of the undertaking or property of the Company within the meaning of Section 252 of the Companies Act nor to provide for a payment giving rise to a duty of a director of the Company pursuant to Section 253 of the Companies Act.
	
			
	JAZZ PHARMACEUTICALS IRELAND LTD.
	EXECUTIVE

	/s/ Shawn Mindus
	 
	/s/ Patricia Carr

	Shawn Mindus
Director   
	 
	Patricia Carr
Vice President, Finance

	Date:   4-May-2016   
	 
	Date:   12 May 2016

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]